Nine months after filing, a last-minute retreat: ophthalmic therapy startup EIR Biopharma withdraws its US$17 million US IPO plan.
Preclinical biotech company EIR Biopharma has withdrawn its US$17 million IPO plan. It had originally intended to offer 3.8 million shares at US$4 to US$5 per share.
EIR Biopharma is a preclinical-stage biotech company focused on developing in-licensed therapies for ophthalmic diseases. The company withdrew its IPO plan on Monday. It had filed in February 2026 to raise US$17 million by offering 3.8 million shares at a price range of US$4 to US$5 per share.
The San Francisco, California-based company was founded in 2022. It had planned to list on the NYSE American but had not yet selected a ticker symbol. Kingswood Capital Markets was slated to be the sole bookrunner for the deal.
Related Articles
.png)
Amid a sharp U.S. stock market selloff, the parent company of "GTA 6" bucked the trend and closed higher! First-day sales of US$3.79 billion set a record, and Wall Street's focus shifted to the next-generation GTA Online.

HK Bull/Bear Outstanding Qty Ratio(48:52) | November 21

NVIDIA Corporation (NVDA.US) has plunged 46% over seven weeks, marking its longest losing streak since the 2008 financial crisis, with US$2.6 trillion in market value wiped out.
Amid a sharp U.S. stock market selloff, the parent company of "GTA 6" bucked the trend and closed higher! First-day sales of US$3.79 billion set a record, and Wall Street's focus shifted to the next-generation GTA Online.
.png)
HK Bull/Bear Outstanding Qty Ratio(48:52) | November 21

NVIDIA Corporation (NVDA.US) has plunged 46% over seven weeks, marking its longest losing streak since the 2008 financial crisis, with US$2.6 trillion in market value wiped out.






